Home
PCRX
PCRX News

Latest Pacira BioSciences Inc. (PCRX) News on October 18, 2024

Argus Research

15 hours ago

Daily – Vickers Top Insider Picks for 10/17/2024

Argus Research

2 days ago

Daily – Vickers Top Insider Picks for 10/16/2024

Argus Research

3 days ago

Daily – Vickers Top Insider Picks for 10/15/2024

Argus Research

4 days ago

Daily – Vickers Top Insider Picks for 10/14/2024

Argus Research

7 days ago

Daily – Vickers Top Insider Picks for 10/11/2024

Argus Research

8 days ago

Daily – Vickers Top Insider Picks for 10/10/2024

Argus Research

9 days ago

Daily – Vickers Top Insider Picks for 10/09/2024

Argus Research

9 days ago

PCRX: Raising target price to $13.00

Argus Research

10 days ago

Daily – Vickers Top Insider Picks for 10/08/2024

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire

11 days ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Argus Research

11 days ago

Daily – Vickers Top Insider Picks for 10/07/2024

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings

Simply Wall St.

13 days ago

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings

Argus Research

14 days ago

Daily – Vickers Top Insider Picks for 10/04/2024

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

GlobeNewswire

15 days ago

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

Argus Research

15 days ago

Daily – Vickers Top Insider Picks for 10/03/2024

Argus Research

16 days ago

Daily – Vickers Top Insider Picks for 10/02/2024

Argus Research

17 days ago

Daily – Vickers Top Insider Picks for 10/01/2024

Argus Research

18 days ago

Daily – Vickers Top Insider Picks for 09/30/2024

Argus Research

21 days ago

Daily – Vickers Top Insider Picks for 09/27/2024

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

GlobeNewswire

22 days ago

Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Argus Research

22 days ago

Daily – Vickers Top Insider Picks for 09/26/2024

DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders

PR Newswire

23 days ago

DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders

Argus Research

23 days ago

Daily – Vickers Top Insider Picks for 09/25/2024

Argus Research

24 days ago

Daily – Vickers Top Insider Picks for 09/24/2024

Argus Research

25 days ago

Daily – Vickers Top Insider Picks for 09/23/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 09/20/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 09/19/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 09/18/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 09/17/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 09/16/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 09/13/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 09/12/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 09/11/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 09/10/2024

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire

a month ago

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

a month ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 09/09/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 09/06/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 09/05/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 09/04/2024

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 09/03/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 08/30/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 08/29/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 08/28/2024

Argus Research

2 months ago

PCRX: Lowering target price to $12.00

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 08/27/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 08/26/2024

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 08/23/2024

Argus Research

2 months ago

PCRX: Rating decreased to a SELL

Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey

GlobeNewswire

2 months ago

Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Zacks

2 months ago

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Pacira BioSciences, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Simply Wall St.

3 months ago

Pacira BioSciences, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues

Zacks

3 months ago

Pacira (PCRX) Q2 Earnings Beat, Exparel Sales Drive Revenues

Associated Press Finance

3 months ago

Pacira: Q2 Earnings Snapshot

Pacira BioSciences Reports Second Quarter 2024 Financial Results

GlobeNewswire

3 months ago

Pacira BioSciences Reports Second Quarter 2024 Financial Results

Argus Research

3 months ago

PCRX: Lowering target price to $21.00

Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024

GlobeNewswire

3 months ago

Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024

Nanotechnology in medicine: Who are the leading public companies?

Medical Device Network

3 months ago

Nanotechnology in medicine: Who are the leading public companies?

Should Value Investors Buy Pacira BioSciences (PCRX) Stock?

Zacks

3 months ago

Should Value Investors Buy Pacira BioSciences (PCRX) Stock?

Argus Research

3 months ago

PCRX: What does Argus have to say about PCRX?

Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025

GlobeNewswire

3 months ago

Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025

Argus Research

3 months ago

PCRX: Lowering target price to $22.00

Argus Research

4 months ago

PCRX: Lowering target price to $24.00

Declining Stock and Decent Financials: Is The Market Wrong About Pacira BioSciences, Inc. (NASDAQ:PCRX)?

Simply Wall St.

4 months ago

Declining Stock and Decent Financials: Is The Market Wrong About Pacira BioSciences, Inc. (NASDAQ:PCRX)?

Insider Sale: Chief Medical Officer Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX)

GuruFocus.com

4 months ago

Insider Sale: Chief Medical Officer Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX)

Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference

GlobeNewswire

5 months ago

Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference

Earnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their Forecasts

Simply Wall St.

5 months ago

Earnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their Forecasts

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029

GlobeNewswire

5 months ago

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029

Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

GlobeNewswire

5 months ago

Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues

Zacks

5 months ago

Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript

Insider Monkey

5 months ago

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript

GuruFocus.com

5 months ago

Pacira BioSciences Inc (PCRX) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth ...

Pacira BioSciences Reports Q1 2024 Results: Aligns with EPS Projections and Announces $150 ...

GuruFocus.com

5 months ago

Pacira BioSciences Reports Q1 2024 Results: Aligns with EPS Projections and Announces $150 ...

Associated Press Finance

5 months ago

Pacira: Q1 Earnings Snapshot

Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program

GlobeNewswire

5 months ago

Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program

Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

GlobeNewswire

5 months ago

Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024

GlobeNewswire

6 months ago

Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024

Argus Research

6 months ago

PCRX: What does Argus have to say about PCRX?

Pacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trend

Simply Wall St.

6 months ago

Pacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trend

Aggressive Stock Portfolio: 13 Stocks Picked by Analysts

Insider Monkey

6 months ago

Aggressive Stock Portfolio: 13 Stocks Picked by Analysts

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire

7 months ago

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag

Zacks

7 months ago

Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

GlobeNewswire

7 months ago

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX)

GuruFocus.com

7 months ago

Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX)

Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference

GlobeNewswire

7 months ago

Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference

11 Best Small Cap Pharma Stocks to Invest In

Insider Monkey

7 months ago

11 Best Small Cap Pharma Stocks to Invest In

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript

Insider Monkey

8 months ago

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript

Pacira BioSciences Full Year 2023 Earnings: EPS Beats Expectations

Simply Wall St.

8 months ago

Pacira BioSciences Full Year 2023 Earnings: EPS Beats Expectations

Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues

Zacks

8 months ago

Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues

Thomson Reuters StreetEvents

8 months ago

Q4 2023 Pacira Biosciences Inc Earnings Call

Pacira BioSciences Inc (PCRX) Reports Record Revenues and Robust Earnings for Full-Year 2023

GuruFocus.com

8 months ago

Pacira BioSciences Inc (PCRX) Reports Record Revenues and Robust Earnings for Full-Year 2023

Associated Press Finance

8 months ago

Pacira: Q4 Earnings Snapshot

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

GlobeNewswire

8 months ago

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

Pacira to Report 2023 Financial Results on Thursday February 29, 2024

GlobeNewswire

8 months ago

Pacira to Report 2023 Financial Results on Thursday February 29, 2024

Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

GlobeNewswire

8 months ago

Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

GlobeNewswire

8 months ago

Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.

Is There Any Hope for Cassava Sciences Stock?

Motley Fool

8 months ago

Is There Any Hope for Cassava Sciences Stock?

Vista Outdoor Inc. (NYSE:VSTO) Q3 2024 Earnings Call Transcript

Insider Monkey

9 months ago

Vista Outdoor Inc. (NYSE:VSTO) Q3 2024 Earnings Call Transcript

G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams

PR Newswire

9 months ago

G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams

A FAMILY'S JOURNEY OF GROWTH AND EXCELLENCE: THE TAYLOR STORY AT SANDRIDGE CRAFTED FOODS®

PR Newswire

9 months ago

A FAMILY'S JOURNEY OF GROWTH AND EXCELLENCE: THE TAYLOR STORY AT SANDRIDGE CRAFTED FOODS®

Share on Social Networks: